Move Over Leptin: Serotonin Takes Center Stage as Target for Weight Loss
This article was originally published in Start Up
Executive SummaryNew research shows that serotonin produced in the brain is the true regulator of bone mass and energy metabolism--not leptin, as has been widely believed. As more details of the leptin-serotonin pathway become known, they could open up the potential for new, more specific molecular targets for the development of obesity drugs with less potential for osteoporosis.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.